Proceedings of the 1986 ISIR-TNO meeting on the interferon system, 7-12 September 1986, Dipoli Congress Center, Espoo, Finland
First Statement of Responsibility
edited by K. Cantell, H. Schellekens.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Dordrecht
Name of Publisher, Distributor, etc.
Springer Netherlands
Date of Publication, Distribution, etc.
1987
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
(592 pages)
CONTENTS NOTE
Text of Note
Genes and Proteins.- Amino acid residues affecting antiviral and antiproliferative activity in interferon-?'s.- Differential structures and activities of three IFN ?2 variants departing only at two amino acid positions.- Selective association of high density lipoprotein with interferon beta serine.- Structure, genetics and function of human ?2 interferon.- Tailoring of alpha interferons via in vivo recombination of the genes.- A new type of interferon-like protein produced by peripheral blood mononuclear cells treated with inhibitors of transcription.- Apparent auto-inhibition of murine interferon-? due to a serum component.- Modes of Action.- Nuclear localization of internalized interferons-? and -?: a role for nuclear receptors.- The 5? end of the human (2?-5?) oligo A synthetase gene contains sequences responsible for transcriptional activation by interferon.- Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon.- The double-stranded RNA dependent protein kinase from human cells.- Homologs to mouse Mx protein induced by interferon in various species.- Comparative studies of the genomic structure of two human interferon induced genes.- Characterization of two new IFN-induced proteins.- Early events in the interaction of IFN-? with IFN-sensitive and IFN-resistant Daudi cells.- Receptors.- Some freshly EBV-transformed B-cell lines lack functional IFN-receptors.- Production of antibodies against the murine IFN-? receptor.- Purification and characterization of the receptor for human interferon-?.- Induction.- Interferon induction by transfection of Sendai virus C gene cDNA.- Studies on the expression of spontaneous interferon-like activity in mouse peritoneal cells.- Cellular factors mediate induction and superinduction of the human interferon-? gene.- Interferon beta-2 is constitutively expressed in human monocytes.- Regulation of human fibroblast growth by autocrine interferon-beta.- Biological activities of human interferon-?2 produced by cDNA expression in hamster cells and possible autocrine functions of this cytokine-induced IFN.- Cell Biology.- Overview of long-term IFN effects on the phenotype of transformed and tumor cells.- Mechanisms for anti-invasive effect of interferon.- Comparison of different modes of interferon delivery by tumor specific monoclonal antibodies.- Characterization of rat monoclonal antibodies to mouse interferon-? and -?.- Immunology and Interaction with other Lymphokines.- Molecular and cellular biology of tumor necrosis factor, interferon-?, and their synergism.- Induction of 26kDa protein mRNA in human cells treated with recombinant human tumour necrosis factor (rTNF).- Interactions of tumor necrosis factor, interferon and interleukin-1 in cell killing.- New relationships among IFN-gamma, TNF and IL-1: Cellular and biochemical effects.- Antagonistic effect of type I interferons on human macrophage activation by interferon-?.- Gamma-interferon regulates secretion of G-CSF in human monocytes on the transcriptional level.- Presence of tumor necrosis factor and lymphotoxin in clinical interferon preparations derived from leukocytes.- Phenotype of ?-interferon producing leukocytes.- Interferon regulates major histocompatibility class I gene expression through a 5? upstream regulatory region.- The antiviral effects of tumor necrosis factors.- Animal Models.- Interferon and tumor necrosis factor alter the phospholipid metabolism in Friend leukemia cell tumors in mice.- Antitumor effects of rat rec.IFN-? in rats bearing transplantable rat tumors.- Mechanisms of anticancer action of interferons on human tumour xenografts in nude mice.- IFN-gamma inhibits osteosarcoma xenografts in nude mice.- Transgenic mice carrying exogenous mouse interferon genes.- Studies on interferon in the bovine species: biological and biochemical effects.- Clinical Studies.- Antitumor effects.- Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon.- Efficacy of alpha interferons in hairy cell leukemia (HCL) and status of the interferon system of patients in remission.- WellferonR efficacy in the treatment of hairy cell leukaemia (HCL).- Detection of urinary enzyme excretion as a parameter of the nephrotoxicity of human interferon alpha-2b in patients with hairy cell leukemia (HCL).- Interferon alfa-N1 WellferonR in Kaposi's sarcoma: single agent or combination with vinblastine.- Combined interferon-polychemotherapy versus polychemotherapy in multiple myeloma: a phase-III study.- Recombinant interferon alpha (2A) combined with dacarbazine in treatment of metastatic melanoma.- Intralesional interferon-alpha-therapy in advanced malignant melanoma.- Comparison of clinical toxicity of natural alpha and recombinant gamma interferon. Results of phase II trials in lung cancer.- Antitumor activity of interferon-? against malignant glioma in combination with chemotherapeutic agent of nitrosourea (ACNU).- Interferon alpha in the treatment of malignant diseases: sources, doses, and regimens.- Treatment of various malignancies with recombinant IFN-?.- Interferons and interferon inactivators in AIDS, ARC and in cancer patients.- Overview: clinical trial with natural and recombinant interferons in China.- Interferon producing capacity in patients with liver disease, diabetes mellitus, chronic diseases and malignant diseases.- Antiviral effects.- Early treatment of the common cold with intranasal interferon alpha-2A (Ro 22-8181): a preliminary pilot study.- Long-term tolerance of intranasal recombinant interferon-?ser in man.- The role of alpha 2 interferon in combination with acyclovir in ophthalmic zoster (an open pilot study).- Production of a partially acid labile alpha interferon in cytomegalovirus pneumonitis.- Randomized controlled trial of a four month course of recombinant human alpha interferon in patients with chronic type B hepatitis.- Treatment of chronic hepatitis B infection with alpha (lymphoblastoid) interferon: responses in different social and ethnic groups in comparison to adenine arabinoside monophosphate.- Interferon alfa-n1 (Wellferon)R in severe recurrent genital warts: Report of a multi-study program.- Activity of intralesional interferon alfa-2B in viral and malignant skin diseases.- Effects on other diseases.- Idiopathic mixed cryoglobulinemia: a new therapeutic approach with alpha interferon.- Treatment of rheumatoid arthritis (RA) with interferon-gamma (IFN-gamma): Results of clinical trials in Germany.- Interferon in human breast cystic disease.- Efficacy of intrathecally administered natural human fibroblast interferon as treatment of multiple sclerosis.- A study on the efficacy of recombinant human ?D type interferon (rIFN-?D) in treatment of chronic cervicitis.- Presence and possible role of interferons in psoriasis.- The components of the interferon system in SLE and psoriasis.- Pharmacokinetics of (123I)-interferon (IFN) alpha-A.- Received after deadline.- 2?5? A synthetase activity is induced by a factor excreted in heat-shocked cells. Comparison of this factor with IFN.- Mapping the action of interferon on primate brain.- Chemical and biological characterization of natural human lymphoblastoid interferon alphas.- Author index.
PARALLEL TITLE PROPER
Parallel Title
Proceedings of the 1986 ISIR-TNO meeting held at the Dipoli Congress Center, Espoo, Finland, September 7-12, 1986